Cellebrite DI (NASDAQ:CLBT) Rating Lowered to Hold at Wall Street Zen

Key Points

• Wall Street Zen has downgraded Cellebrite DI's stock rating from "buy" to "hold," reflecting a cautious outlook on the investment potential.
• Analysts have set new target prices for Cellebrite DI, with Lake Street Capital lowering it to $22.00 and Needham & Company reducing it to $18.00, while the consensus price target remains at $22.40.
• Cellebrite DI reported earnings of $0.12 per share, surpassing estimates, with a revenue increase of 18.4% year-over-year, reaching $113.28 million for the quarter.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research report issued to clients and investors on Saturday.

Several other research analysts have also issued reports on the stock. Needham & Company LLC dropped their price target on shares of Cellebrite DI from $24.00 to $18.00 and set a "buy" rating for the company in a research report on Thursday, August 14th. Lake Street Capital lowered their price target on shares of Cellebrite DI from $24.00 to $22.00 and set a "buy" rating on the stock in a research note on Friday, August 15th. Five analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $22.40.

Cellebrite DI Trading Up 3.5%

NASDAQ CLBT traded up $0.61 during trading hours on Friday, reaching $17.87. The company's stock had a trading volume of 1,567,153 shares, compared to its average volume of 1,818,868. The business has a 50-day simple moving average of $15.37 and a 200 day simple moving average of $16.94. Cellebrite DI has a 52 week low of $13.10 and a 52 week high of $26.30. The stock has a market cap of $4.28 billion, a PE ratio of -23.51, a PEG ratio of 3.14 and a beta of 1.28.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last posted its quarterly earnings results on Thursday, August 14th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.01. Cellebrite DI had a positive return on equity of 23.92% and a negative net margin of 34.56%.The company had revenue of $113.28 million for the quarter, compared to analysts' expectations of $112.33 million. During the same quarter in the prior year, the company earned $0.10 earnings per share. The firm's revenue was up 18.4% on a year-over-year basis. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities analysts predict that Cellebrite DI will post 0.3 EPS for the current year.

Institutional Trading of Cellebrite DI

A number of large investors have recently added to or reduced their stakes in CLBT. Squarepoint Ops LLC purchased a new position in shares of Cellebrite DI in the second quarter worth about $675,000. Ashford Capital Management Inc. increased its stake in shares of Cellebrite DI by 2.2% in the second quarter. Ashford Capital Management Inc. now owns 1,265,670 shares of the company's stock worth $20,251,000 after purchasing an additional 27,830 shares in the last quarter. SkyView Investment Advisors LLC increased its stake in shares of Cellebrite DI by 2.6% in the second quarter. SkyView Investment Advisors LLC now owns 37,708 shares of the company's stock worth $597,000 after purchasing an additional 970 shares in the last quarter. Tidal Investments LLC grew its stake in Cellebrite DI by 60.9% during the second quarter. Tidal Investments LLC now owns 96,157 shares of the company's stock valued at $1,539,000 after acquiring an additional 36,402 shares in the last quarter. Finally, Select Equity Group L.P. purchased a new position in Cellebrite DI during the second quarter valued at approximately $5,558,000. Hedge funds and other institutional investors own 45.88% of the company's stock.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.